Evidence map›Paper›PMID 28392161›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017

Functional Delivery of Lipid-Conjugated siRNA by Extracellular Vesicles.

Aisling J O'Loughlin, Imre Mäger, Olivier G de Jong, Miguel A Varela, Raymond M Schiffelers, Samir El Andaloussi, Matthew J A Wood, Pieter Vader

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 4 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 198 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024
    Review
  18. Review
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 4 countries.

Aisling J O'LoughlinDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK.
Imre MägerDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK; Institute of Technology, University of Tartu, Tartu 50411, Estonia.
Olivier G de JongDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK.
Miguel A VarelaDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK.
Raymond M SchiffelersDepartment of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands.
Samir El AndaloussiDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK; Department of Laboratory Medicine, Clinical Research Center, Karolinska Institutet, SE-141 57 Stockholm, Sweden.
Matthew J A WoodDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK. Electronic address: matthew.wood@dpag.ox.ac.uk.
Pieter VaderDepartment of Physiology, Anatomy and Genetics, University of Oxford, OX1 3QX Oxford, UK; Department of Clinical Chemistry and Haematology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands. Electronic address: pvader@umcutrecht.nl.
University of Oxford · GBUniversity Medical Center Utrecht · NLUniversity of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are cell-derived, membranous nanoparticles that mediate intercellular communication by transferring biomolecules, including proteins and RNA, between cells. As a result of their suggested natural capability to functionally deliver RNA, EVs may be harnessed as therapeutic RNA carriers. One major limitation for their translation to therapeutic use is the lack of an efficient, robust, and scalable method to load EVs with RNA molecules of interest. Here, we evaluated and optimized methods to load EVs with cholesterol-conjugated small interfering RNAs (cc-siRNAs) by systematic evaluation of the influence of key parameters, including incubation time, volume, temperature, and EV:cc-siRNA ratio. EV loading under conditions that resulted in the highest siRNA retention percentage, incubating 15 molecules of cc-siRNA per EV at 37°C for 1 hr in 100 μL, facilitated concentration-dependent silencing of human antigen R (HuR), a therapeutic target in cancer, in EV-treated cells. These results may accelerate the development of EV-based therapeutics.

Indexed as

Drug Delivery SystemsAnimalsBase SequenceBiological TransportCell LineCell Line, TumorCholesterolELAV-Like Protein 1Extracellular VesiclesFibroblastsGene ExpressionHEK293 CellsHumansMiceNeoplasm ProteinsNeuronsCholesterolELAVL1 protein, humanELAV-Like Protein 1Neoplasm ProteinsRNA, Small Interferingdeliveryexosomesextracellular vesiclesRNA interferencesiRNA

Identifiers

PMID28392161
PMCPMC5498810
OpenAlexW2603213989

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.